R&D Trends

WHO urges action against HIV drug resistance threat

Tuesday, July 25, 2017

WHO alerts countries to the increasing trend of resistance to HIV drugs detailed in a report based on national surveys conducted in several countries. The Organization warns that this growing threat could undermine global progress in treating and preventing HIV infection if early and effective action is not taken.

[Read More]

Aptevo, Alligator to develop tumor-directed immunotherapy bispecific antibody

Monday, July 24, 2017

Aptevo Therapeutics, a biotechnology company focused on developing novel immuno-oncology and hematology therapeutics, and Alligator Bioscience, a biotechnology company developing antibody-based pharmaceuticals for tumor-directed immunotherapy, have entered into an agreement to co-develop a novel immunotherapy bispecific antibody candidate, ALG.APV-527, based on Alligator’s first generation bispecific antibody, ATOR-1016. The new bispecific candidate was developed using Aptevo’s bispecific technology platform and includes proprietary binding elements generated by Alligator’s ALLIGATOR-GOLD antibody library. Initiation of cell line development for the manufacturing of clinical material is expected to begin shortly.

[Read More]

Takeda, Schrödinger form research collaboration

Friday, July 21, 2017

Takeda Pharmaceutical and Schrödinger, a privately held company dedicated to revolutionizing drug discovery through advanced computational methods, announced the formation of a multi-target research collaboration directed to diseases that align with Takeda’s core therapeutic areas of interest. The unique collaboration will combine Schrödinger’s in silico platform-driven drug discovery capabilities with Takeda’s deep therapeutic area knowledge and expertise in structural biology. With a focus on simplicity, speed and agility, Schrödinger will lead the multi-target discovery effort with Takeda providing protein crystal structures to aid Schrödinger in using its computational platform to guide the design of new chemical entities. Schrödinger will be responsible for its discovery costs.

[Read More]

Report: 74% of medicines in development could be first-in-class treatments

Thursday, July 20, 2017

Seventy-four percent of medicines in clinical development around the world are potentially first-in-class medicines, meaning they use a completely new approach to fighting a disease, according to a new report by The Analysis Group, commissioned by the Pharmaceutical Research and Manufacturers of America (PhRMA). The Biopharmaceutical Pipeline: Innovative Therapies in Clinical Development report examines the global state of the drug development pipeline and provides insights into new approaches biopharmaceutical researchers are pursuing.

[Read More]

UK Biobank partners with the EGA

Thursday, July 20, 2017

Genomic data from the 500,000 people participating in the UK Biobank initiative will be distributed via the European Genome–phenome Archive (EGA), a resource developed jointly by the European Bioinformatics Institute (EMBL-EBI) and the Centre for Genomic Regulation (CRG). UK Biobank provides extremely detailed, high-quality datasets on individuals. It is an unprecedented collection that offers endless possibility and substantial efficiency savings for biomedical research and understanding the causes of disease.

[Read More]

GB Sciences, Worldwide Clinical Trials partner on cannabis-based therapy trials

Thursday, July 20, 2017

GB Sciences has signed a Consulting Services Agreement with Worldwide Clinical Trials to evaluate the company’s intellectual property portfolio and to assist with pre-IND planning for its proprietary cannabis-based formulations. These pre-IND consulting services will be performed by the chief medical and scientific officer (CMSO) of Worldwide, Michael F. Murphy, M.D., Ph.D., as the representative of an extended Worldwide team. Dr. Murphy has participated in the IND application process for multiple small molecules and biologics with 19 therapeutic targets, across five divisions of the FDA. Dr. Murphy was also the Clinical Research and Excellence (CARE) Lifetime Achievement Award recipient for 2017. The award is presented annually to an extraordinary individual with exceptional contributions and a consistent history of service to the clinical research industry throughout their career.

[Read More]